论文部分内容阅读
目的:研究中药复方肝癌宁对人肝癌细胞体内、外生长及其对甲胎蛋白(AFP)分泌的影响.方法:以小鼠移植人肝癌模型观察药物(每天10,5,2.5 g/kg)的体内抗肝癌作用.以MTT法测定复方肝癌宁(45 g/L)的体外抗肝癌活性,以ELISA检测AFP分泌量.结果:10 g/kg对小鼠移植人肝癌HepG_2移植瘤的生长有明显抑制作用,抑瘤率为54.5% (P<0.01),且呈量效关系(r=10,P<0.01).与空白对照组相比,复方肝癌宁45 g/L作用4,5,6 d时体外培养的人肝癌HepG_2细胞株的生长明显抑制(7.0±1.3 vs 10.3±0.9,P<0.05;12.1±0.4 vs 21.3±0.9,P<0.01;15.2±0.3 vs 45.6±0.6,P<0.01),AFP分泌量也明显减少(39.6±1 vs 54.5±3;20.8±2 vs 45.6±4;18.5±2 vs 40.2±3:均P<0.01).结论:中药复方肝癌宁能明显的抑制肝癌HepG_2细胞生长及AFP分泌水平.
Objective: To study the effect of hepatocarcinix on the growth of human hepatocarcinoma cells in vitro and in vivo and its effect on the secretion of AFP. Methods: The effect of anti-hepatoma in vivo on the transplanted human hepatocellular carcinoma model (10, 5 and 2.5 g / kg) was observed. The anti-hepatocarcinoma activity of compound HGF (45 g / L) in vitro was determined by MTT assay, and the secretion of AFP was detected by ELISA. Results: The inhibitory rate of 10 g / kg on the growth of HepG2 transplanted human hepatoma in mice was 54.5% (P <0.01), and the dose - effect relationship was significant (r = 10, P < 0.01). Compared with the blank control group, the growth of HepG_2 cells cultured in vitro was significantly inhibited at 45 g / L for 45 h and 6 d (7.0 ± 1.3 vs. 10.3 ± 0.9 , P <0.05; 12.1 ± 0.4 vs 21.3 ± 0.9, P <0.01; 15.2 ± 0.3 vs 45.6 ± 0.6, P <0.01 ), AFP secretion was also significantly reduced (39.6 ± 1 vs 54.5 ± 3; 20.8 ± 2 vs 45.6 ± 4; 18.5 ± 2 vs 40.2 ± 3: P <0. 01). Conclusion: HCC Ningpi can significantly inhibit HepG_2 cell growth and AFP secretion.